Q-omics provides the consensus-scored CMTM5 profile across patient tissues and cancer cell-line models. CMTM5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CMTM5 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, CMTM5 RNA expression shows 12,235 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where CMTM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CMTM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CMTM5 survival associations across molecular data types. CMTM5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CMTM5 RNA expression–survival associations across cancer types. High CMTM5 expression shows unfavorable associations in ACC, BLCA and UCEC, but favorable associations in UVM, LUAD and LGG. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CMTM5 RNA expression.
This table summarizes CMTM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CMTM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CMTM5 shows lower tumor expression in BLCA, COAD, KICH, THCA, LUAD and KIRP. The BLCA box plot shows higher CMTM5 RNA expression in normal versus tumor tissue (log2 FC = −1.191, t-test p < 0.001).
This table shows molecular features associated with CMTM5 in patient tissues and cancer cell lines. In patient samples, CMTM5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CMTM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
